POLYMED.NSEPoly Medicure Ltd.
POLYMED.NSE
Poly Medicure Ltd.158
Pharma feels supply pain despite duty relief
New Delhi: Maintaining a steady supply of essential petrochemical inputs amid the West Asia conflict remains a concern for India's pharmaceutical industry, even though the government has waived customs duties on several of these products until June 30, according to industry executives.They said that while the duty waiver provides some cost relief to the sector, the main challenge is securing supplies and ensuring their timely movement."The government's decision to waive duties on select petrochemical products demonstrates its commitment to standing by the pharma industry but the far bigger challenge lies in ensuring the supply and timely movement of these materials," said Mehul Shah, a pharma industry expert.Shah pointed out that Saudi chemical giant SABIC declaring force majeure on methanol and styrene validates the industry's supply concerns.The disruption to shipping at the Strait of Hormuz has hit production of chemicals globally, especially in West Asia and Asia.The government on Thursday announced a temporary waiver on customs duty on over 40 critical petrochemical products, including anhydrous ammonia, methanol, styrene and polymers like PVC and PET chips.Namit Joshi, chairman of Pharmaceuticals Export Promotion Council of India (Pharmexcil), said it the duty waiver will be helpful only if the exporting nations maintain their invoicing price. "Unfortunately, that is beyond our control.
cityfalcon.com·2d ago
Why Did Poly Medicure Shares Crash 44% Despite Strong Long Term Growth?
Synopsis: Poly Medicure, with a market cap of ₹16,077 cr and 14 global manufacturing facilities, saw its stock fall ~44% due to moderated revenue growth of 5–6% in H1FY26. Strategic acquisitions and India–EU trade deal opportunities position it for 15–16% full-year growth. Poly Medicure, a key player in India’s medical devices sector, has recently faced significant […] The post Why Did Poly Medicure Shares Crash 44% Despite Strong Long Term Growth? appeared first on Trade Brains .
cityfalcon.com·2mo ago
Buyer Not A Consumer If Purchase Made For Profit: SC
File Photo Of Supreme Court Of India New Delhi- In a significant verdict, the Supreme Court on Thursday held that if any purchase of goods or services is for profit generation, then the purchaser cannot be held to be a consumer and consequently cannot pursue cases under the Consumer Protection Act. A bench of Justices JB Pardiwala and Manoj Misra, delivering the judgement in an appeal filed by M/s Poly Medicure Ltd, affirmed the findings of the State and National Consumer Disputes Redressal Commissions that the complaint filed by the company was not maintainable under the Act. It held that a company purchasing software to automate its business processes cannot be regarded as a “consumer” under the Consumer Protection Act, 1986, as such a transaction is for a “commercial purpose”. Authoring the verdict, Justice Manoj Misra referred to various judgements and said, “the transaction of purchase of goods/ services (i.e., software) had a nexus with generation of profits and, therefore, qua that transaction the appellant cannot be considered a consumer as defined in Section 2(1)(d) of the 1986 Act.” If the transaction has a nexus with generation of profits, it would be treated as one for a commercial purpose, it said while dismissing the appeal of the firm.
cityfalcon.com·5mo ago
Stocks to buy: Nagaraj Shetti recommends Poly Medicure, Oil India shares to buy
India's stock market remained stable after four days of losses, with Nifty 50 down 0.29% and BSE Sensex down 0.33%. Investor confidence was affected by U.S. visa fee hikes, foreign selling, and tariffs. Experts suggest cautious optimism for recovery in the IT sector and private banks.
cityfalcon.com·6mo ago
<
...
1
>